Drug Trial Radar · NCT01087801
A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers
Last checked: Nov 19, 2026Latest source record: Dec 6, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Oct 2007
Primary completion
Nov 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- ChiRhoClin, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The following are the study hypothesis: * Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples being predominantly of exocrine pancreas origin when samples are duodenal aspirates. * Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples meeting the minimum specifications for use in the indicated laboratory test of DNA mutational analysis.
Conditions
- Pancreatic Disease
Interventions
ChiRhoStimDrug
Human Secretin for Injection
PlaceboDrug
Saline for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endoscopic SampleTime frame: First 5 minutes after treatment administration
- Volume of Fluid ≥ 3.5mL (Boolean Expression Evaluated as Yes or no).Time frame: First 5 minutes after treatment administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Saint Louis University
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.